Cui, Ran http://orcid.org/0000-0002-3236-4082
Elzur, Roy A. http://orcid.org/0000-0002-6474-9876
Kanai, Masahiro http://orcid.org/0000-0001-5165-4408
Ulirsch, Jacob C. http://orcid.org/0000-0002-7947-0827
Weissbrod, Omer
Daly, Mark J. http://orcid.org/0000-0002-0949-8752
Neale, Benjamin M. http://orcid.org/0000-0003-1513-6077
Fan, Zhou
Finucane, Hilary K. http://orcid.org/0000-0003-3864-9828
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5 - 5DP5OD024582-04, DP5 - 5DP5OD024582-04)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (1U01HG011719-01, 1U01HG011719-01)
Simons Foundation (SFARI 704413, SFARI 704413)
Heiwa Nakajima Foundation
Article History
Received: 24 October 2022
Accepted: 26 October 2023
First Online: 30 November 2023
Competing interests
: J.C.U. is an employee of Illumina. O.W. is an employee and holds equity in Eleven Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora, consultant of the scientific advisory board for Camp4 Therapeutics and consultant for Merck. The other authors declare no competing interests.